Magnetoliposomes containing calcium ferrite nanoparticles for applications in breast cancer therapy

• Autor(a) principal: Pereira, Daniela S.M.
• Data de Publicação: 2018
• Outros Autores: Cardoso, Beatriz D., Rodrigues, Ana Rita O., Amorim, Carlos O., Amaral, Vítor S., Almeida, Bernardo G., Queiroz, Maria João R.P., Martinho, Olga, Baltazar, Fátima, Calhelha, Ricardo C., Ferreira, Isabel C.F.R., Coutinho, Paulo J.G., Castanheira, Elisabete M.S.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10198/20266
• topic: Breast cancer therapy; Calcium ferrite nanoparticles; Magnetoliposomes; New antitumor drugs; Thienopyridine derivatives

Magnetoliposomes containing calcium ferrite (CaFe2O4) nanoparticles were developed and characterized for the first time. CaFe2O4 nanoparticles were covered by a lipid bilayer or entrapped in liposomes forming, respectively, solid or aqueous magnetoliposomes as nanocarriers for new antitumor drugs. The magnetic nanoparticles were characterized by UV/Visible absorption, XRD, HR-TEM, and SQUID, exhibiting sizes of 5.2 +/- 1.2 nm (from TEM) and a superparamagnetic behavior. The magnetoliposomes were characterized by DLS and TEM. The incorporation of two new potential antitumor drugs (thienopyridine derivatives) specifically active against breast cancer in these nanosystems was investigated by fluorescence emission and anisotropy. Aqueous magnetoliposomes, with hydrodynamic diameters around 130 nm, and solid magnetoliposomes with sizes of ca. 170 nm, interact with biomembranes by fusion and are able to transport the antitumor drugs with generally high encapsulation effciencies (>=70%). These fully biocompatible drug-loaded magnetoliposomes can be promising as therapeutic agents in future applications of combined breast cancer therapy.